Patents by Inventor Joyce MEESTERS
Joyce MEESTERS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230374131Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.Type: ApplicationFiled: February 14, 2023Publication date: November 23, 2023Inventors: Edward Norbert VAN DEN BRINK, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
-
Patent number: 11613575Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.Type: GrantFiled: August 19, 2019Date of Patent: March 28, 2023Assignee: GENMAB A/SInventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
-
Publication number: 20220169738Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: ApplicationFiled: July 7, 2021Publication date: June 2, 2022Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
-
Patent number: 11091553Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: GrantFiled: December 5, 2017Date of Patent: August 17, 2021Assignee: GENMAB A/SInventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
-
Patent number: 11046771Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: GrantFiled: December 5, 2017Date of Patent: June 29, 2021Assignee: GENMAB A/SInventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
-
Publication number: 20200199229Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.Type: ApplicationFiled: August 19, 2019Publication date: June 25, 2020Inventors: Edward Norbert VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Isil ALTINTAS, Paul PARREN, Rik RADEMAKER
-
Publication number: 20200123255Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.Type: ApplicationFiled: September 25, 2019Publication date: April 23, 2020Inventors: Edward VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Paul PARREN
-
Patent number: 10590206Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.Type: GrantFiled: January 9, 2014Date of Patent: March 17, 2020Assignee: GENMAB A/SInventors: Aran Frank Labrijn, Joyce Meesters, Joost J. Neijssen, Edward Norbert Van Den Brink, Janine Schuurman, Paul Parren
-
Patent number: 10465006Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.Type: GrantFiled: July 4, 2014Date of Patent: November 5, 2019Assignee: GENMAB A/SInventors: Edward Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Paul Parren
-
Patent number: 10407501Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.Type: GrantFiled: January 8, 2015Date of Patent: September 10, 2019Assignee: GENMAB A/SInventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
-
Publication number: 20180215827Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: ApplicationFiled: December 5, 2017Publication date: August 2, 2018Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
-
Publication number: 20180194845Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: ApplicationFiled: December 5, 2017Publication date: July 12, 2018Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
-
Publication number: 20180179286Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: ApplicationFiled: December 5, 2017Publication date: June 28, 2018Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
-
Patent number: 9862769Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.Type: GrantFiled: May 27, 2011Date of Patent: January 9, 2018Assignee: GENMAB A/SInventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
-
Publication number: 20160333095Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.Type: ApplicationFiled: January 8, 2015Publication date: November 17, 2016Applicant: GENMAB A/SInventors: Edward Norbert VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Isil ALTINTAS, Paul PARREN, Rik RADEMAKER
-
Publication number: 20160168247Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.Type: ApplicationFiled: July 4, 2014Publication date: June 16, 2016Inventors: Edward VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Paul PARREN
-
Publication number: 20150337049Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.Type: ApplicationFiled: January 9, 2014Publication date: November 26, 2015Inventors: Aran Frank LABRIJN, Joyce MEESTERS, Joost J. NEIJSSEN, Edward Norbert VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
